期刊文献+

本底选择对^99mTc-MIBI显像预测鼻咽癌多重耐药的影响

Influence of different backgrounds of ^(99m)Tc-MIBI SPECT on predicting the efficacy of neoadjuvant chemotherapy for nasopharyngeal carcinoma
下载PDF
导出
摘要 目的:选择合理的判断指标和可行的图像分析方法,评价^(99m)Tc-MIBI核素显像预测鼻咽癌多重耐药的可能性。方法:选取32例病理证实为局部晚期鼻咽癌的患者,治疗前行^(99m)Tc-MIBI核素显像,在病灶最明显的横断面图像上获取病灶的放射性计数,以脑部、斜方肌、肺部作为本底分别计算早期、延迟显像的肿瘤摄取比值和清除率,以MRI结果作为疗效评价标准,绘制受试者工作特征(receiver operating characteristic,ROC)曲线选择合适的图像分析方法。结果:高反应组的早期和延迟期摄取比值均大于低反应组,差异有统计学意义,而高反应组与低反应组之间清除率差异无统计学意义。ROC曲线分析显示,早期和延迟摄取比值诊断化疗耐药性,均以脑部为本底时效果最佳;曲线下面积分别为0.943(SE=0.042;95%CI:0.860~1.026;P=0.002)和0.929(SE=0.050;95%CI:0.831~1.027;P=0.02),最佳诊断值分别为23.29和19.14;前者灵敏度为91.4%,特异度为80.0%,后者灵敏度为85.7%,特异度为77.3%。结论:以脑部为本底计算^(99m)TcMIBI摄取比值是诊断鼻咽癌新辅助化疗耐药性的理想指标。 Objective:To investigate the influence of different backgrounds of double-phase technetium-^99m methoxyisobutylisonitrile (^99mTc-MIBI) SPECT on predicting the efficacy of neoadjuvant chemotherapy for nasopharyngeal carcinoma.Methods:Thirty-two patients of nasopharyngeal carcinoma proven by pathology were chosen. All patients adopted double-phase^99mTc-MIBI SPECT before chemotherapy. The regions of interest (ROIs) drawn in the transverse slices with obvious lesions were copied to cerebrum, trapezius and lung. The relationships between efifcacy of neoadjuvant chemotherapy and the early uptake ratio, late uptake ratio and washout rate of^99mTc-MIBI were evaluated. The receiver operating characteristic (ROC) curve was made according to MRI results to determine the cutoff value of diagnosis.Results:The high response group had higher early uptake ratio and late uptake ratio than the low response group. The early uptake ratio of^99mTc-MIBI was best when cerebrum was set as background. The area under ROC curve (ROC-AUC) was 0.943 (SE=0.042; 95%CI=0.860-1.026;P=0.002). The sensitivity and speciifcity were 91.4% and 80.0%, respectively. The late uptake ratio of99mTc-MIBI was best when cerebrum was set as background, with AUC of 0.929 (SE=0.050; 95%CI=0.831-1.027;P=0.02), sensitivity of 85.7%, and speciifcity of 77.3%.Conclusion:When cerebrum is chosen as background, the uptake ratio of^99mTc-MIBI on predicting the efifcacy of chemotherapy for nasopharyngeal carcinoma is a perfect index.
出处 《肿瘤影像学》 2016年第2期150-155,共6页 Oncoradiology
关键词 多重耐药 鼻咽癌 ^99M锝-甲氧基异丁基异腈 本底 Multidrug resistance Nasopharyngeal carcinoma Technetium-99m methoxyisobutylisonitrile Background
  • 相关文献

参考文献15

  • 1SUAREZ C, RODRIGO J P, RINALDO A, et al. Current treatment options for recurrent nasopharyngeal cancer [J]. Enr Arch Otorhinolaryngol, 2010, 267(12): 1811-1824.
  • 2WILKINSON B A, HAMDY F C, State-of-the-art staging in prostate cancer [J]. BJU Int, 2001, 87(5): 423- 430.
  • 3KIM Y S, CliO S W, LEE K J, et al. Tc-99m MIBI SPECT is useful for noninvasivdy predicting the presence of MDR1 gene-encoded P-glycoprotein in patientswith hepatocel]ular carcinoma [J]. Clin Nucl Med, 1999, 24(11): 874-879.
  • 4杜承润,应红梅,程竞仪,周珺珺,蒋津津,王孝深,胡超苏.双时相^(99m)Tc-MIBI SPECT/CT显像预测局部晚期鼻咽癌对含多西他赛新辅助化疗敏感性的价值[J].中国癌症杂志,2013,23(10):834-840. 被引量:11
  • 5DU C, YING H, ZHOU J, et al. Prediction of the response to docetaxel-based chemotherapy for locoregionally advanced nasopharyngeal carcinoma: the role of double-phase 99'nTc-MIBI SPECT/CT [J]. Med Oncol, 2014, 31(2): 833.
  • 6申勇,孙伟莉,袁超,徐慧琴,刘斌.^(99m)Tc-MIBI评价2-脱氧-D-葡萄糖对鼻咽癌耐药株多药耐药的逆转作用及机制[J].中国药理学通报,2015,31(10):1433-1438. 被引量:4
  • 7CERIANI L, GIOVANELLA L, BANDERA M, et al. Semi-quantitative assessment of 99mTc-sestamibi uptake in lung cancer: relationship with clinical response to chemotherapy [J]. Nucl Med Commun, 1997, 18(11): 1087-1097.
  • 8SOHAIB M, WIQAR M A, ALI M K, et al. A single 99~Tc-MIBI study to predict response to neoadjuvant treatment in sarcoma patiens U]. Hell J Nucl Med, 2011, 14(2): 140-145.
  • 9LISTEWNIK M H, BIRKENFELD B, FOSZCZYI~SKA-KLODA M. Response of malignant breast tumours to neoadjuvant chemotherapy evaluated with Tc-99m MIBI [J]. Ann Acad Med Stetin, 2011,57(1): 73-78.
  • 10YANG T J, AUKEMA T S, VAN TINTEREN H, et al. Predicting early chemotherapy response with technetium- 99m methox~isobutylisonitrile SPECT/CT in advanced non-small cell lung cancer [J]. Mol Imaging Biol, 2010, 12(2): 174-180,.

二级参考文献19

  • 1胡永成.骨肉瘤化疗效果的影像学评价[J].中华骨科杂志,2004,24(9):569-571. 被引量:4
  • 2林开文,刘保平,程兵.乳腺癌^(99)Tc^m-MIBI显像与P-gp、MRP表达的关系[J].中华核医学杂志,2005,25(5):288-290. 被引量:6
  • 3Bacci G,Longhi A,Versari M,et al.Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy:15-year experience in 789 patients treated at a single institution.Cancer,2006,106:1154-1161.
  • 4Rosen G,Caparros B,Huvos AG,et al.Preoperative chemotherapy for osteogenic sarcoma:selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy.Cancer,1982,49:1221-1230.
  • 5Huvos AG.Bone tumors:diagnosis,treatment,and prognosis.2nd.Phliladephia:WB senuders,1991:125-140.
  • 6(O)zcan Z,Burak Z,Erin(c) R,et al.Correlation of 99Tcm-sestamibi uptake with blood-pool and osseous phase 99Tcm-MDP uptake in malignant bone and soft-tissue tumours.Nucl Med Commun,2001,22:679-683.
  • 7S(o)derlund V,Larsson SA,Bauer HC,et al.Use of 99Tcm-MIBI scintigraphy in the evaluation of the response of osteosarcoma to chemotherapy.Eur J Nucl Med,1997,24:511-515.
  • 8Punyaratabandhu T,Wittayawongsaruji S,Rajchadara S,et al.The correlation of 99Tcm-MIBI scintigraphy and histological response in determining the percentage of tumor necrosis in osteosarcoma after preoperative chemotherapy.J Med Assoc Thai,2005,88(3):53-62.
  • 9Burak Z,Moretti JL,Ersoy O,et al.99Tcm-MIBI imaging as a predictor of therapy response in osteosarcoma compared with multidrug resistance-associated protein and P-glycoprotein expression.J Nucl Med,2003,44:1394-1401.
  • 10陈丽波,赵劼,孙辉,高识,温强,赵国庆,马庆杰.^99Tc^m-MIBI显像用于分化型甲状腺癌复发与P—gp表达的关系研究[J].中华核医学杂志,2008,28(6):393-396. 被引量:3

共引文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部